By IDSE News Staff
The FDA approved a three-drug, delayed-release regimen for the treatment of Helicobacter pylori infection in adults.
The drug, omeprazole magnesium-amoxicillin-rifabutin (Talicia, RedHill Biopharma), is the only rifabutin-based therapy approved for the treatment of H. pylori infection. The drug is designed to address the high resistance of H. pylori bacteria to regimens containing clarithromycin, according to RedHill. The company said it plans to launch